이뮨온시아
Financials
Valuation Metrics
이뮨온시아's Market Cap is ₩2376B. Ranked #728 of 2,410 in KR market (top 30%), #315 of 1,631 on KOSDAQ (top 19%), #79 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 34%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 237.65B KRW | KR#728/2,410 Sec#79/231 |
| Revenue | 111.2M KRW | KR#2,383/2,410 Sec#224/231 |
| Net Income | -27.36B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 33.15B KRW | KR#2,309/2,410 Sec#217/231 |
| Net Assets | 28.42B KRW | KR#2,185/2,410 Sec#198/231 |
| Value | ||
| P/B | 8.36x | KR#2,339/2,410 Sec#209/231 |
| P/S | 2136.94x | KR#2,401/2,410 Sec#227/231 |
| FCF Yield | -9.72% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -96.30% | KR#2,330/2,410 Sec#216/231 |
| ROA | -82.55% | KR#2,380/2,410 Sec#225/231 |
| Op. Margin | -25182.04% | KR#2,379/2,410 Sec#223/231 |
| Financial Health | ||
| Debt Ratio | 16.65% | KR#287/2,410 Sec#43/231 |
| Total Debt | 0 KRW | KR—/2,410 Sec—/231 |
| FCF | -23.10B KRW | KR#1,924/2,410 Sec#187/231 |
| Cash | 8.24B KRW | KR#1,796/2,410 Sec#159/231 |
| Current Ratio | 6.22x | KR#201/2,410 Sec#39/231 |
| Performance | ||
| 1Y Return | -53.72% | KR#2,066/2,410 Sec#188/231 |
| 1M Return | -24.53% | KR#2,114/2,410 Sec#210/231 |
| From 52W High | -83.22% | KR#2,344/2,410 Sec#220/231 |
| 1Y MDD | -83.48% | KR#2,330/2,410 Sec#215/231 |
| Trading | ||
| Volume | 254,588 shares | KR#288/2,410 Sec#25/231 |
| Trading Value | 651.7M KRW | KR#708/2,410 Sec#75/231 |
| Foreign Own. | 3.36% | KR#1,181/2,410 Sec#110/231 |
| Per Share | ||
| EPS | -299 KRW | KR—/2,410 Sec—/231 |
| BPS | 311 KRW | KR#2,395/2,410 Sec#230/231 |
Company Info
IMMUNEONCIA, established in 2016, is a specialized company developing antibody-based immune-oncology drugs, slated for KOSDAQ listing in 2025 as a technology growth company. It holds Anti-PD-L1, Anti-CD47, and Anti-LAG-3 monoclonal antibodies as core assets, generating revenue through new drug candidate development and early clinical technology transfers. IMMUNEONCIA aims to be the first domestic leader in commercializing Anti-PD-L1 immune-oncology drugs and is concentrating on research and development to launch global blockbuster new drugs. Its headquarters are located in Yongin-si, Gyeonggi-do.